Olfactory training improve cognitive impairment in Alzheimer's disease by modulating the Medial septum-Hippocampal cholinergic circuit

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400094486

Enrollment

Unknown

Registered

2024-12-24

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease

Interventions

Olfactory training group:Olfactory training was conducted using the Smell Training Kit (Soul Nutrients, UK). Patients were exposed to four different scents (phenylethyl alcohol—rose, eucalyptol—eucaly

Placebo group:The patients in the placebo group will follow the same procedure as the olfactory training group, using odorless containers. The containers and labels are identical to those used in the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria for MCI of AD origin: Based on Petersen's diagnostic criteria for MCI and the ATN biomarker research diagnostic criteria: 1. Evidence of cognitive impairment reported by the patient or an informant, or detected by an experienced clinician; 2. Objective evidence of impairment in one or more cognitive domains; 3. Mild impairment in complex instrumental activities of daily living, but the ability to maintain independent daily living remains; 4. Does not meet the diagnostic criteria for dementia; 5. Amyloid PET-positive.

Exclusion criteria

Exclusion criteria: 1. History of any neurodegenerative diseases other than AD or a history of stroke; 2. Diseases significantly affecting cognitive function, including vitamin B12 deficiency, stroke, neurosyphilis, etc.; 3. Severe psychiatric disorders, including schizophrenia, bipolar disorder, severe depression, and anxiety; 4. Conditions significantly affecting the sense of smell, such as active upper respiratory tract/sinus infections or respiratory distress at the time of testing, congenital or traumatic anosmia, known nasal polyps or tumors, and alcohol or substance dependence; 5. Refusal to undergo blood tests; 6. Refusal to sign the informed consent form.

Design outcomes

Primary

Measure	Time frame
Cognitive Function;	—

Secondary

Measure	Time frame
Activity of Daily Living;Behavioral and psychological symptoms;Olfactory function;	—

Countries

China

Contacts

Public ContactYuping Ning

Affiliated Brain Hospital of Guangzhou Medical University

ningjeny@126.com+86 20 8157 0720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026